- Home
- BRSP vs UPB Comparison
BRSP vs UPB Comparison
Compare BRSP & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- UPB
- Stock Information
- Founded
- BRSP 2017
- UPB 2021
- Country
- BRSP United States
- UPB United States
- Employees
- BRSP N/A
- UPB N/A
- Industry
- BRSP Real Estate Investment Trusts
- UPB
- Sector
- BRSP Real Estate
- UPB
- Exchange
- BRSP Nasdaq
- UPB NYSE
- Market Cap
- BRSP 561.8M
- UPB 521.3M
- IPO Year
- BRSP 2018
- UPB 2024
- Fundamental
- Price
- BRSP $5.09
- UPB $10.83
- Analyst Decision
- BRSP Buy
- UPB Strong Buy
- Analyst Count
- BRSP 4
- UPB 4
- Target Price
- BRSP $6.83
- UPB $56.50
- AVG Volume (30 Days)
- BRSP 442.4K
- UPB 367.7K
- Earning Date
- BRSP 07-29-2025
- UPB 05-06-2025
- Dividend Yield
- BRSP 12.60%
- UPB N/A
- EPS Growth
- BRSP N/A
- UPB N/A
- EPS
- BRSP N/A
- UPB N/A
- Revenue
- BRSP $340,600,000.00
- UPB $2,296,000.00
- Revenue This Year
- BRSP N/A
- UPB N/A
- Revenue Next Year
- BRSP $12.19
- UPB N/A
- P/E Ratio
- BRSP N/A
- UPB N/A
- Revenue Growth
- BRSP N/A
- UPB N/A
- 52 Week Low
- BRSP $4.16
- UPB $5.14
- 52 Week High
- BRSP $6.71
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- BRSP 48.05
- UPB N/A
- Support Level
- BRSP $4.98
- UPB N/A
- Resistance Level
- BRSP $5.21
- UPB N/A
- Average True Range (ATR)
- BRSP 0.13
- UPB 0.00
- MACD
- BRSP -0.01
- UPB 0.00
- Stochastic Oscillator
- BRSP 37.72
- UPB 0.00
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.